Navigation Links
Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Date:9/8/2009

ted antibodies in combination with a wide range of anti-cancer agents, including many commonly prescribed chemotherapeutic drugs. This patent was granted to the University of Texas System and is exclusively licensed to Peregrine Pharmaceuticals.

The Phase II trial of bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients has a Simon two-stage design. In the first stage, 15 patients with advanced breast cancer were enrolled and treated with the combination regimen. Nine of the 14 (64%) evaluable patients in this cohort demonstrated an objective tumor response according to RECIST criteria, exceeding the pre-specified primary efficacy endpoint needed to expand enrollment in the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall.

"Completion of patient enrollment in our second Phase II breast cancer study marks another milestone for the bavituximab cancer program, with two of our three ongoing Phase II trials now having completed enrollment," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "We believe the rapid enrollment experienced in all three of these trials is representative of the enthusiasm of our clinical investigators as well as the need for improved cancer therapies. We look forward to reporting further data from these studies in the upcoming months."

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. They may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... LONDON, Dec. 15 Thomson ... Pharma ® has become the first drug pipeline ... and outcome information. This highly anticipated new content ... this month. ,, Thomson Pharma ... from registries, publications, press releases, conferences, and other ...
(Date:12/14/2009)... International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced today ... Scripps Research Institute ("Scripps") by entering into an ... Dyadic,s patented and proprietary C1 fungus ("C1"). ,, ... relationship between the two organizations which began in ... the C1 genome for the first time. The ...
(Date:12/14/2009)... Dec. 14 Nektar Therapeutics (Nasdaq: ... been appointed to serve on its board of ... leader with over 35 years of experience in ... brings to Nektar extensive industry perspective at an ... W. Robin, President and CEO of Nektar and ...
(Date:12/11/2009)... -- Dendreon Corporation (Nasdaq: DNDN ) announced ... public offering have exercised in full their option ... stock at the public offering price of $24.75 ... increases the size of the offering to an ... Dendreon expects to receive net proceeds from the ...
Breaking Biology Technology:Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... Neurosciences, Inc. Launches a Self-Guided Lesson as Prep for ... ... 13 In recognition that physician,comfort and knowledge with techniques ... with cervical dystonia (CD), Solstice,Neurosciences, Inc. (Solstice) has created MYOBLOC(TM) ...
... December 13 Synosia Therapeutics today,announced the appointment ... business officer, effective immediately., Dr Blanc, who ... Basel,Switzerland, joins from Syngenta, where he created and ... training and an,experienced biotech entrepreneur, Dr. Blanc helped ...
... SAN DIEGO, Dec. 13 Neurocrine Biosciences,Inc. (Nasdaq: ... from the U.S. Food and Drug Administration (FDA) indicating,that ... and 10 mg capsules,for the treatment of insomnia is ... 15, 2006, the Company received an action letter from ...
Other Biology Technology:New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia 2New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia 3Synosia Therapeutics Announces Appointment of Chief Business Officer 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 3
(Date:12/15/2009)... consumers can look forward to ultra-low powered or ... and mobile phones. This is made possible with ... are critical elements for power optimisation and higher ... Analog IC design is the key enabling capability ... the nation in advanced analog and mixed signal ...
(Date:12/14/2009)... University of Alberta researchers are part of an international ... not fossilized bones, to revise the history of North ... of U of A Earth and Atmospheric Sciences professor ... theory, based on radiocarbon dating of bones and teeth. ... large mammals in North America (the ,megafauna,) disappeared about ...
(Date:12/14/2009)... can be transmitted by sneezing, touching, or for ... a habit that may have driven the dinosaurs to ... Jacqueline Upcroft, a member of f1000 Biology, highlights the ... in PLoS One. This led them to deduce that ... jaw bones seen in many tyrannosaurid fossils. , The ...
Breaking Biology News(10 mins):NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3JustAnswer 28R 29 and Glaucoma Research Foundation Help Individuals See the Light in Preventing Blindness 49011 1JustAnswer 28R 29 and Glaucoma Research Foundation Help Individuals See the Light in Preventing Blindness 49011 2JustAnswer 28R 29 and Glaucoma Research Foundation Help Individuals See the Light in Preventing Blindness 49011 3JustAnswer 28R 29 and Glaucoma Research Foundation Help Individuals See the Light in Preventing Blindness 49011 4Sunesis to Present at the Jefferies 3rd Annual Healthcare Conference 12643 1Sinus Infections Can Cause Toxic Shock in Kids 49007 1Sinus Infections Can Cause Toxic Shock in Kids 49007 2
... at the spectacular recovery of certain coral reefs in Australia,s ... event in 2006. , That year high sea temperatures caused ... the southern part of the GBR. The damaged reefs ... an event that can spell the total loss of the ...
... 7, 2009 -- A recent study conducted in the ... conditions on both cultivated and uncultivated soils, vastly advancing ... is an important soil attribute that is related to ... of the essential processes that determine soil quality. During ...
... Heller, an acclaimed chemical engineering research professor and professor ... been elected a fellow into the American Academy of ... laureate Nelson Mandela, actor James Earl Jones, U.S. Secretary ... "Dr. Heller is an outstanding scientist who translates his ...
Other Biology News:Reef boom beats doom 2Impact of floods on soils 2University of Texas at Austin engineer elected to American Academy of Arts and Sciences 2University of Texas at Austin engineer elected to American Academy of Arts and Sciences 3
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... systems provide linking and labelling reagents ... specific primary antibodies for visualising cellular ... accomplished using an ultra-sensitive indirect labelling ... technology. Secondary antibodies are polymerised directly ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Biology Products: